Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-02
2006-05-02
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S321000
Reexamination Certificate
active
07037917
ABSTRACT:
This invention concerns the use of compounds of formulathe N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3wherein R3is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.
REFERENCES:
patent: 4659363 (1987-04-01), Hubele et al.
patent: 5017466 (1991-05-01), Kobayashi et al.
patent: 5691364 (1997-11-01), Buckman et al.
patent: 6048866 (2000-04-01), Hutchings et al.
patent: 6093716 (2000-07-01), Davis et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 6200977 (2001-03-01), Cushing et al.
patent: 6528513 (2003-03-01), Cushing et al.
patent: 6835726 (2004-12-01), Cushing et al.
patent: 0 135 472 (1984-07-01), None
patent: 0135472 (1985-03-01), None
patent: 0 588 762 (1993-08-01), None
patent: 0371139 (1994-10-01), None
patent: 0834507 (1998-04-01), None
patent: 0945442 (1999-09-01), None
patent: 0945443 (1999-09-01), None
patent: WO 95/10506 (1995-04-01), None
patent: WO 98/41512 (1998-09-01), None
Arnold, et al., Inhibitor conformational flexibility and positional variation are important for activity against drug-resistant virus: crystal structures of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase, 21stEuropean Crystallographic Meeting, Durban, South Africa, 24-29, Aug. 2003.
Arnold, Conformational Flexibility of DAPYs: activity against resistant HIV, Aug. 2003.
Blagovic, et al.,Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnuceloside Inhibitor TMC125, J. Am. Chem. Soc. 2003, vol. 125, pp. 6016-6017.
Clark, Inhibitor conformational flexibility and positional variation are important for activity against drug-resistant virus: crystal structures of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase, 21stEuropean Crystallographic Meeting, Durban, S. Africa, 24-29, Aug. 2003.
Das, et al., Could multiple modes of binding of a potent NNRTI TMC125-R165335 explain its potency against common drug-resistant mutants?, CROI, Boston, Feb. 2003.
M-P de Bethune, TMC 125 resistance profiles, Resistance, Mexico, Jun. 2003.
Furukawa, et al., Syntheses of Compounds related to Guanidine and their Inhibitory Action on Growth of HeLa Cells, Chem. Pharm. Bull. 9 (11), 914-921 (1951).
Gazzard, et al., TMC125, A Next-Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI, CROI, Seattle, Feb. 2002.
Gazzard, et al.,An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance, AIDS 2003, vol. 17, pp. 49-54.
Gazzard, et al., TMC125, a Next Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1 Infected Individuals with Phenotypic NNRTI-Resistance, XIV International AIDS Conference, Jul. 7-11, 2003, Barcelona, Spain.
Gazzard, TMC 125 C207 study treatment-experienced, CROI Seattle, Feb. 2002.
Gazzard, 7 day treatment-experienced, WAC Barcelona, Jul. 2002.
Gruzdev, et al.,A Randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive HIV-1 infected subjects, AIDS 2003, vol. 17, pp. 2487-2494.
Gulick, New Antiretroviral Drugs, Clinical Microbiology and Infectious Diseases, CMI, 9, (3) pp. 186-193 (Mar. 2003).
Lange, TMC 125 decay rate vs ERA, CROI Seattle, Feb. 2002.
Lewi, Potency & multiple binding modes of TMC 125, CROI Boston, Feb. 2003.
Ludovici, et al.,Evolution of Anti-HIV Drug Candidates. Part 3: Diarylpyrimidine (DAPY) Analogues, Bioorganic & Medical Chemistry Letters 11, 2001, pp. 2235-2239.
Sankatsing, et al., TMC 125 Monotherapy for One Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy With a 5-Drug Regimen, CROI, Seattle, Feb., 2002.
Sankatsing, et al.,TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen, AIDS 2003, vol. 17, pp. 2623-2627.
TMC 125 for 7 days in HIV-1+ individuals with NNRTI resistance (TMC 125- C207), AIDS, 17 (18): F49-54, Dec. 5, 2003.
TMC 125 as 7d monotherapy in ARV-naive subjects (TMC 125-C208), AIDS, 17(17): 2487-2494, Nov. 21, 2003.
TMC 125 similar potency to 5-drug, 3-class regimen, AIDS, 17(18): 2623-2627 Dec. 5, 2003.
Udier-Blagovic, et al., Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125,J. Am Chem. Soc. 2003, vol. 125, pp. 6016-6017.
Vingerhoets, et al., Antiviral activity of TMC125, a potent next-generation NNRTI, against > 5000 recombinant clinical isolates exhibiting a wide range of (NNRTI) resistance, XIIth International HIV Drug Resistance Workshop, Jun. 10-14, 2003, Mexico.
Vingerhoets, et al., Antiviral activity of TMC Against a Panel of Site-Directed Mutants Encompassing Mutations Observed In Vitro and In Vivo, Poster No. 621, Presented at the XIth Conference on Retrovirus and Opportunistic Infections, Feb. 8-11, 2004, San Francisco, CA USA.
Vingerhoets, Antiviral activity TMC 125 SDM CROI, San Francisco, Feb. 2004.
Vingerhoets, et al., Characterization of Resistance Before and After Short-Term Therapy with TMC125 in Patients with Documented NNRTI Resistance, XIIth International HIV Drug Resistance Workshop, Jun. 10-14, 2003, Mexico.
Vingerhoets, Resistance before/after therapy—TMC 125C207, XII Resistance Mexico, Jun. 2003.
Vingerhoets, Resistance profile clinical isolates TMC 125, XII Resistance, Jun. 2003, Mexico.
Vingerhoets, TMC-125-C207 resistance analysis, Resistance, Jun. 2003, Mexico.
Udier-Blagovic, et al., Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125,J. Am< Chem. Soc. 2003, vol. 125, pp. 6016-6017.
De Corte Bart
De Jonge Marc Rene
Heeres Jan
Ho Chih Yung
Janssen Paul Adriaan Jan
Balasubramanian Venkataraman
Donnelly Laura
Janssen Pharmaceutica N.V.
LandOfFree
HIV replication inhibiting pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV replication inhibiting pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV replication inhibiting pyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582211